[1]刘登科,牛虹博,葛正茂,等.曲霉菌对唑类药物的耐药机制最新研究进展[J].现代检验医学杂志,2020,35(02):161-164.[doi:10.3969 / j.issn.1671-7414.2020.02.044]
 LIU Deng-ke,NIU Hong-bo,GE Zheng-mao,et al.Recent Advances in the Mechanism of Aspergillus Resistance to Azole Drugs[J].Journal of Modern Laboratory Medicine,2020,35(02):161-164.[doi:10.3969 / j.issn.1671-7414.2020.02.044]
点击复制

曲霉菌对唑类药物的耐药机制最新研究进展()
分享到:

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年02期
页码:
161-164
栏目:
综 述
出版日期:
2020-05-24

文章信息/Info

Title:
Recent Advances in the Mechanism of Aspergillus Resistance to Azole Drugs
文章编号:
1671-7414(2020)02-161-04
作者:
刘登科牛虹博葛正茂刘宇鹏
(中国人民解放军联勤保障部队第967 医院ICU,辽宁大连 116000)
Author(s):
LIU Deng-keNIU Hong-boGE Zheng-maoLIU Yu-peng
(ICU of the 967 Hospital, the Joint Logistic Support Force of the People’s Liberation Army of China,Liaoning Dalian 116000, China)
关键词:
曲霉菌唑类药物耐药机制cyp51hapE
分类号:
R379;R446.5
DOI:
10.3969 / j.issn.1671-7414.2020.02.044
文献标志码:
A
摘要:
侵袭性曲霉菌病(invasive Aspergillosis, IA)是一种死亡率极高的机会性感染疾病,疾病早期诊断率低,其病原体曲霉菌广泛存在于自然界中。多烯类、唑类和棘白菌素是治疗侵袭性曲霉菌病的主要药物,其中唑类药物在临床应用较多。近年流行病学调查发现,不仅侵袭性曲霉菌病发病率逐年上升,而且曲霉菌对唑类药物的耐药率也逐渐增加,其耐药形势日益严峻,对人类健康造成了极大威胁。其中,曲霉菌的外排系统、生物膜的产生、基因的改变以及环境的选择作用等因素都参与了曲霉菌对唑类药物的耐药。因此,该文针对曲霉菌对唑类药物耐药机制的最新研究进展作以简要综述,以期为曲霉菌耐药菌株的监测以及新型治疗药物作用靶点的研制提供理论基础。

参考文献/References:

[1] KWON-CHUNG K J, SUGUI J A. Aspergillusfumigatus--what makes the species a ubiquitous humanfungal pathogen[J]. PLoS Pathogens, 2013, 9(12):e1003743.
[2] 徐媛,陈敏,廖万清.中国侵袭性曲霉菌病流行病学现状[J].中国真菌学杂志,2018,13(1):57-60.   XU Yuan, CHEN Min, LIAO Wanqing. Epidemiologyof invasive Aspergillosis in China [J]. Chinese Journalof Mycology, 2018,13(1):57-60.
[3] 马梦亭,王凤超.临床患者血流真菌感染的实验诊断及治疗研究进展[J].现代检验医学杂志,2019,34(4):161-164.   MA Mengting, WANG Fengchao. Advances inexperimental diagnosis and treatment of blood flowfungal infection in clinical patients [J]. Journal ofModern Laboratory Medicine, 2019,34(4):161-164.
[4] 娄鉴芳,梅亚宁,张世昌,等.不同实验室环境下ELISA 法检测血清GM 结果的可靠性研究[J].现代检验医学杂志,2019,34(1):101-103.   LOU Jianfang, MEI Yaning, ZHANG Shichang, etal. Reliability study on serum GM results by ELISAmethod in different laboratory conditions [J]. Journal ofModern Laboratory Medicine, 2019,34(1):101-103.
[5] RIVERO-MENENDEZ O, ALASTRUEY-IZQUIERDOA, MELLADO E, et al. Triazole resistance in Aspergillusspp: A worldwide problem?[J]. Journal of Fungi(Basel, Switzerland), 2016, 2(3): 21.
[6] SHISHODIA S K, TIWARI S, SHANKAR J. Resistancemechanism and proteins in Aspergillus species againstantifungal agents[J]. Mycology, 2019, 10(3): 151-165.
[7] MISCH E A, SAFDAR N. Updated guidelines for thediagnosis and management of Aspergillosis[J]. Journalof Thoracic Disease, 2016, 8(12): E1771-E1776.
[8] 张丽,王贺,肖盟,等.E-test 方法与微量肉汤稀释法检测念珠菌属对唑类抗真菌药物的敏感性评价[J]. 现代检验医学杂志,2019,34(4):67-70.   ZHANG Li , WANG He, XIAO Meng, et al .Comparison of E-test and broth microdilution methodfor antifungal susceptibility testing of Candida speciesto azoles [J]. Journal of Modern Laboratory Medicine,2019,34(4):67-70.
[9] 陈勇,韩黎.深部真菌医院感染及其耐药性现状[J].中国消毒学杂志,2016,33(4):372-375.   CHEN Yong, HAN Li. Nosocomial infections ofdeep fungi and their drug resistance status[J]. ChineseJournal of Disinfection. 2016,33(4):372-375.
[10] CANNON R D, LAMPING E, HOLMES A R, et al. Efflux-mediated antifungal drug resistance[J]. ClinicalMicrobiology Reviews, 2009, 22(2): 291-321.
[11] CHAMILOS G, KONTOYIANNIS D P. Update onantifungal drug resistance mechanisms of Aspergillusfumigatus[J]. Drug Resistance Updates, 2005, 8(6): 344-358.
[12] TOBIN M B, PEERY R B, SKATRUD P L. Genes encodingmultiple drug resistance-like proteins in Aspergillusfumigatus and Aspergillus flavus[J]. Gene, 1997,200(1/2): 11-23.
[13] SLAVEN J W, ANDERSON M J, SANGLARD D, et al.Increased expression of a novel Aspergillus fumigatusABC transporter gene, atrF, in the presence of itraconazolein an itraconazole resistant clinical isolate[J].Fungal Genetics and Biology, 2002, 36(3): 199-206.
[14] NASCIMENTO A M, GOLDMAN G H, PARK S, etal. Multiple resistance mechanisms among Aspergillusfumigatus mutants with high-level resistance to itraconazole[J]. Antimicrobial Agents and Chemotherapy,2003, 47(5): 1719-1726.
[15] RAJENDRAN R, MOWAT E, MCCULLOCH E, etal. Azole resistance of Aspergillus fumigatus biofilmsis partly associated with efflux pump activity[J].Antimicrobial Agents and Chemotherapy, 2011, 55(5):2092-2097.
[16] SUN Nuo, LI Dongmei, FONZI W, et al. Multidrugresistanttransporter mdr1p-mediated uptake of a novelantifungal compound[J]. Antimicrobial Agents andChemotherapy, 2013, 57(12): 5931-5939.
[17] PAUL S, LUDE?A Y, VILLENA G K, et al. Highqualitydraft genome sequence of a biofilm forminglignocellulolytic Aspergillus higer strain ATCC 10864[J].Standards in Genomic Sciences, 2017, 12(1): 37.
[18] KAUR S, SINGH S. Biofilm formation by Aspergillusfumigatus[J]. Medical Mycology, 2014, 52(1): 2-9.
[19] MOWAT E, BUTCHER J, LANG S, et al. Developmentof a simple model for studying the effects of antifungalagents on multicellular communities of Aspergillusfumigatus[J]. Journal of Medical Microbiology, 2007,56(Pt 9): 1205-1212.
[20] BEAUVAIS A, SCHMIDT C, GUADAGNINI S, etal. An extracellular matrix glues together the aerialgrownhyphae of Aspergillus fumigatus[J]. CellularMicrobiology, 2007, 9(6): 1588-1600.
[21] 喻玮,楼亚玲,裘云庆,等.曲霉菌对唑类抗真菌药物的耐药机制研究进展[J].中国抗生素杂志,2018,43(7):801-805.   YU Wei, LOU Yaling, QIU Yunqing, et al. Researchprogress on the mechanism of Aspergillus fungiresistant to azoles family antifugal agents [J]. ChineseJournal of Antibiotics,2018,43(7):801-805.
[22] LINDEN J W, ARENDRUP M C, WARRIS A, et al.Prospective multicenter international surveillance ofazole resistance in Aspergillus fumigatus[J]. EmergingInfectious Diseases, 2015, 21(6): 1014-1041.
[23] SNELDERS E, KARAWAJCZYK A, SCHAFTENAARG, et al. Azole resistance profile of amino acid changesin Aspergillus fumigatus CYP51A based on proteinhomology modeling[J]. Antimicrobial Agents andChemotherapy, 2010, 54(6): 2425-2430.
[24] CHOWDHARY A, SHARMA C, HAGEN F, et al. Exploringazole antifungal drug resistance in Aspergillusfumigatus with special reference to resistance mechanisms[J]. Future Microbiology, 2014, 9(5): 697-711.
[25] WARRILOW A G, MELO N, MARTEL C M, et al.Expression, purification, and characterization of Aspergillusfumigatus sterol 14-alpha demethylase (CYP51)isoenzymes A and B[J]. Antimicrobial Agents and Chemotherapy,2010, 54(10): 4225-4234.
[26] BUIED A, MOORE C B, DENNING D W, et al. Highlevelexpression of cyp51B in azole-resistant clinicalAspergillus fumigatus isolates[J]. The Journal ofAntimicrobial Chemotherapy, 2013, 68(3): 512-514.
[27] HORTSCHANSKY P, ANDO E, TUPPATSCH K, et al.Deciphering the combinatorial DNA-binding code ofthe CCAAT-binding complex and the iron-regulatorybasic region leucine zipper (bZIP) transcription factorHapX[J]. The Journal of Biological Chemistry, 2015,290(10): 6058-6070.
[28] CAMPS S M, DUTILH B E, ARENDRUP M C, etal. Discovery of a HapE mutation that causes azoleresistance in Aspergillus fumigatus through wholegenome sequencing and sexual crossing[J]. PLoS One,2012, 7(11): e50034.
[29] GSALLER F, HORTSCHANSKY P, FURUKAWA T, etal. Sterol biosynthesis and azole tolerance is governed bythe opposing actions of SrbA and the CCAAT bindingcomplex[J]. PLoS Pathogens, 2016, 12(7): e1005775.
[30] 陈先华,牛军,郝飞.烟曲霉菌对唑类抗真菌药的耐药机制研究进展[J].中华临床医师杂志(电子版),2016,10(3):418-423.   CHEN Xianhua, NIU Jun, HAO Fei. Progress inthe mechanisms of azole antifungal drug resistancein Aspergillus fumigatus [J]. Chinese Journal ofClinicians(Electronic Edition), 2016,10(3):418-423.
[31] CHEN Yong, LU Zhongyi, ZHAO Jingjun, et al. Epidemiologyand molecular characterizations of azoleresistance in clinical and environmental Aspergillusfumigatus isolates from China[J]. Antimicrobial Agentsand Chemotherapy, 2016, 60(10): 5878-5884.
[32] HAGIWARA D, TAKAHASHI H, FUJIMOTO M, etal. Multi-azole resistant Aspergillus fumigatus harboringCyp51A TR46/Y121F/T289A isolated in Japan[J]. Journalof Infection and Chemotherapy, 2016, 22(8): 577-579.
[33] LAMOTH F, JUVVADI P R, FORTWENDEL J R, etal. Heat shock protein 90 is required for conidiationand cell wall integrity in Aspergillus fumigatus[J].Eukaryotic Cell, 2012, 11(11): 1324-1332.
[34] XIONG Quanbo, HASSAN S A, WILSON W K, et al.Cholesterol import by Aspergillus fumigatus and itsinfluence on antifungal potency of sterol biosynthesisinhibitors[J]. Antimicrobial Agents and Chemotherapy,2005, 49(2): 518-524.
[35] WILLGER S D, PUTTIKAMONKUL S, KIM K , et al.A sterol-regulatory element binding protein is requiredfor cell polarity, hypoxia adaptation, azole drugresistance, and virulence in Aspergillus fumigatus[J].PLoS Pathogens, 2008, 4(11): e100020.

备注/Memo

备注/Memo:
作者简介:刘登科(1986-),男,本科,主治医师,从事耐药菌株的监测及呼吸急危重症学研究,E-mail:ldking2005@163.com。通讯作者:刘宇鹏(1974-),男,硕士,主任医师,从事急诊及重症医学研究,E-mail:616081896@qq.com。收稿日期:2020-01-06修回日期:2020-01-24
更新日期/Last Update: 2020-04-30